AlphaMeld Corporation
Krishnan Nandabalan serves as the President, Chairman, and CEO of AlphaMeld Corporation since April 2017 and is also a Board Member at Invea Therapeutics and BioXcel Therapeutics, Inc. Additionally, Krishnan is the Founder, Chairman, President, and CEO of Invea Therapeutics and holds the position of President, CEO, and Founder at InveniAI LLC. Prior experience includes serving as a Board Member and Co-Founder of BioXcel Corporation and as Vice President of Corporate Development at Genaissance Pharmaceuticals. Krishnan began their career at CuraGen Corporation as Group Leader of Functional Genomics. Education credentials include a Ph.D. in Biochemistry and Molecular Biology from the Indian Institute of Science, post-doctoral fellowships at Yale University and the University of Kentucky, and both a BSc and MSc in Microbiology from Tamil Nadu Agricultural University.
This person is not in any offices
AlphaMeld Corporation
Headquartered in Guilford, CT, AlphaMeld® Corporation (a wholly owned subsidiary of InveniAI LLC) stands as a global frontrunner in the application of AI, machine learning, and generative AI tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, the company utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company's pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. About The AlphaMeld® Platform The AlphaMeld platform employs a comprehensive approach to generate testable hypotheses, considering factors such as the ideal mode of pharmacotherapy, disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies. This is done while factoring in medical, scientific, strategic, and commercial considerations.